PATENT CLAIM ANALYSIS

Application Number: 16406695
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-11
Patent Classification: ["435", "006100"]

Abstract:
The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.

Claim (Index 6):
The method of  claim 1 , wherein the therapeutically effective amount is at least 5 mg/kg infliximab.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 100.0
- Lexical Diversity: 1.29787
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16406698', '16406700', '14382105', '14652298', '15039919']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5961339926316499
- 35 USC 102 Novelty (BERT): 0.6284537400145408
- Combined Prediction Score: 0.599365967369939
- Mean Citation Score: 401.918542
- Max Citation Score: 595.2871
- Similarity Product: 524.5133886588335

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test